Atara Biotherapeutics annual operating margin
2022
2023
2024
2025
Atara Biotherapeutics's operating margin was 29.69% for fiscal 2025.
View full Atara Biotherapeutics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 29.69% | +94.40 pp |
| 2024 | 2024-12-31 | −64.71% | +3154.77 pp |
| 2023 | 2023-12-31 | −3,219.48% | −2778.23 pp |
| 2022 | 2022-12-31 | −441.25% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −749.21% | −767.40 pp |
| Q1 2026 | 2026-03-31 | −652.91% | −692.44 pp |
| Q4 2025 | 2025-12-31 | −160.69% | −123.43 pp |
| Q3 2025 | 2025-09-30 | −103.50% | −49.37 pp |
| Q2 2025 | 2025-06-30 | 18.19% | +81.85 pp |
| Q1 2025 | 2025-03-31 | 39.53% | +153.75 pp |
| Q4 2024 | 2024-12-31 | −37.26% | +1372.95 pp |
| Q3 2024 | 2024-09-30 | −54.14% | +3201.80 pp |
| Q2 2024 | 2024-06-30 | −63.66% | +7398.62 pp |
| Q1 2024 | 2024-03-31 | −114.22% | +6004.70 pp |
| Q4 2023 | 2023-12-31 | −1,410.21% | +32770.34 pp |
| Q3 2023 | 2023-09-30 | −3,255.94% | −1358.16 pp |
| Q2 2023 | 2023-06-30 | −7,462.28% | −7399.98 pp |
| Q1 2023 | 2023-03-31 | −6,118.92% | −4912.74 pp |
| Q4 2022 | 2022-12-31 | −34,180.54% | — |
| Q3 2022 | 2022-09-30 | −1,897.78% | — |
| Q2 2022 | 2022-06-30 | −62.30% | — |
| Q1 2022 | 2022-03-31 | −1,206.18% | — |
Across the available reported history, Atara Biotherapeutics's operating margin increased from −64.71% to 29.69%, a change of +94.40 percentage points. The latest reported quarter, Q2 2026, shows −749.21%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Atara Biotherapeutics filings at SEC.gov ↗